GILEAD | Medical Information

Epclusa® (sofosbuvir/velpatasvir) Coadministration with Nirmatrelvir+Ritonavir

This document is in response to your request for information regarding Epclusa® (sofosbuvir/velpatasvir [SOF/VEL]) and coadministration with nirmatrelvir+ritonavir.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

PK DDI Evaluation

Drug interaction studies have not been conducted between the single-tablet regimen SOF/VEL and nirmatrelvir+ritonavir. Based on the PK profile of each active ingredient within SOF/VEL and nirmatrelvir+ritonavir, a PK interaction may be predicted.[1,2] Concentrations of nirmatrelvir may increase due to inhibition of P-gp by VEL. However, the clinical significance of this interaction is unknown. For more information about nirmatrelvir+ritonavir, please refer to its product labeling.[2]

With regard to ritonavir, per the SOF/VEL Prescribing Information, no clinically significant drug interactions have been observed between SOF/VEL and atazanavir/ritonavir, nor between SOF/VEL and darunavir/ritonavir. Drug interaction studies have not been conducted between the single-tablet regimen SOF/VEL and ritonavir alone. For more information about nirmatrelvir+ritonavir, please refer to its product labeling.[1,2]

SOF/VEL PK[1]

DDI Mechanism		SOF	VEL
Drug Transporters	P-gp/BCRP	Substrate	Substrate/Inhibitor
	OATP1B1	N/A	Inhibitor
	OATP1B3	N/A	Inhibitor
	OATP2B1	N/A	Inhibitor
Drug Metabolizing Enzymes	CYP1A2	N/A	N/A
	CYP2B6	N/A	Substrate
	CYP2C8	N/A	Substrate
	CYP2C19/19	N/A	N/A
	CYP2D6	N/A	N/A
	CYP3A4	N/A	Substrate

Relevant SOF/VEL Label Information[1]

There is no information in the SOF/VEL product labeling about the coadministration of SOF/VEL and nirmatrelvir+ritonavir.

Based on drug interaction studies conducted with the components of EPCLUSA (sofosbuvir or velpatasvir) or EPCLUSA, no clinically significant drug interactions have been observed or are expected with the following drugs: EPCLUSA: atazanavir/ritonavir, darunavir/ritonavir.

Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. For more information, please refer to Section 7.3 of the SOF/VEL US Prescribing Information (Established and Potentially Significant Drug Interactions).

Available Data

There are no Gilead studies evaluating the coadministration of SOF/VEL and nirmatrelvir+ritonavir.

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and February 21, 2025 using search terms that included Epclusa, velpatasvir, sofosbuvir, nirmatrelvir,ritonavir, and related search terms. No relevant citations in were found.

References

1. Enclosed. Gilead Sciences Inc, EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use. US Prescribing Information. Foster City, CA.
2. Pfizer Labs (Division of Pfizer, Inc.) PAXLOVID (nirmatrelvir tablets; ritonavir tablets), copackaged for oral use. US Prescribing Information. New York, NY.

Abbreviations

BCRP=breast cancer resistance protein
DDI=drug-drug interaction
OATP=organic anion transporting polypeptide
P-gp=P-glycoprotein
PK=pharmacokinetic(s)
SOF=sofosbuvir
VEL=velpatasvir

Product Label

For the full indication, important safety information, and Boxed Warning(s), please refer to the Epclusa US Prescribing Information available at:
http://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3 or 🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.